Clinical Trials in Rimouski, Quebec
17 recruiting
Showing 1–17 of 17 trials
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca1,850 enrolled60 locationsNCT06465810
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled196 locationsNCT06136559
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
Resolution of InflammationReduction of Cell Proliferation
SCF Pharma200 enrolled1 locationNCT05161702
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled217 locationsNCT06793215
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting
Phase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Peripheral Arterial DiseaseInflammationAtherosclerosis of Extremities
Population Health Research Institute6,150 enrolled70 locationsNCT04774159
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acute Coronary Syndrome
DalCor Pharmaceuticals2,000 enrolled223 locationsNCT05918861
Recruiting
Phase 4
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
cognitive healthBrain Fog
Samuel Fortin48 enrolled2 locationsNCT06695910
Recruiting
Not Applicable
Glyceryl Eicosapentaenoate Based Topic Products As an Irritant-free Cream and Serum for Hydration of Sensitive Skin
Skin Dryness
SCF Pharma33 enrolled1 locationNCT06219213
Recruiting
Not Applicable
Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema
Eczema
SCF Pharma16 enrolled1 locationNCT06155513